Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a large surgical database may lead to a reassessment of that practice.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

February is American Heart Month. Sister Bay’s David Lienau wasn’t even aware that his heart health was in jeopardy. But ...

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...